These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 685512)

  • 1. [Clinical and socio-medical aspects of long term uricostatic treatment of primary gout (a 5-10 year study)].
    Klein G; Rainer F; Schmid P; Schneider G
    Z Rheumatol; 1978; 37(5-6):165-73. PubMed ID: 685512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with recurrent hospital admissions for gout: a case-control study.
    Hutton I; Gamble G; Gow P; Dalbeth N
    J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa.
    Gröbner W; Walter-Sack I; de Vries JX
    Eur J Med Res; 1998 Feb; 3(1-2):77-80. PubMed ID: 9512972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.
    Riedel AA; Nelson M; Joseph-Ridge N; Wallace K; MacDonald P; Becker M
    J Rheumatol; 2004 Aug; 31(8):1575-81. PubMed ID: 15290738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of allopurinol on the indicators of immunity in podagra and experimental hyperuricemia].
    Siniachenko OV; Nikolenko IuI; Diadyk AI; Bortnik VA; Okushko RV
    Revmatologiia (Mosk); 1991; (1):12-5. PubMed ID: 2068454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute gout in hospitalized patients.
    Petersel D; Schlesinger N
    J Rheumatol; 2007 Jul; 34(7):1566-8. PubMed ID: 17610315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term treatment of 20 cases of gout with allopurinol].
    Yoshimura T; Akaoka I; Nishizawa T; Nishida T
    Ryumachi; 1973 Apr; 13(2):168-82. PubMed ID: 4730440
    [No Abstract]   [Full Text] [Related]  

  • 12. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D; Sripradit S; Angthararak S
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of piroxicam in the treatment of acute gout.
    Cobra CJ; Cobra JF; Cobra Neto C
    Eur J Rheumatol Inflamm; 1983; 6(1):126-33. PubMed ID: 6861811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The long term administration of allopurinol in primary gout].
    Kono H; Hosoya T; Ikeda H; Ichida K; Miyahara T
    Ryumachi; 1986 Apr; 26(2):84-94. PubMed ID: 3092369
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities for improving medication use and monitoring in gout.
    Singh JA; Hodges JS; Asch SM
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent control of hyperuricemia in the treatment of gout.
    Bull PW; Scott JT
    J Rheumatol; 1989 Sep; 16(9):1246-8. PubMed ID: 2681764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.
    Rozenberg S; Roche B; Dorent R; Koeger AC; Borget C; Wrona N; Bourgeois P
    Rev Rhum Engl Ed; 1995 May; 62(5):392-4. PubMed ID: 7655872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gout - a surgical problem].
    Flügel M; Geldmacher J
    Handchirurgie; 1978; 10(1):15-8. PubMed ID: 689495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
    Li-Yu J; Clayburne G; Sieck M; Beutler A; Rull M; Eisner E; Schumacher HR
    J Rheumatol; 2001 Mar; 28(3):577-80. PubMed ID: 11296962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.